Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Clinical significance of nucleophosmin/B23 and human epidermal growth factor receptor 2/neu expressions in gastric cancers.

Zhou F, Qiu W, Sun L, Xiang J, Sun X, Sui A, Ding A, Yue L.

APMIS. 2013 Jul;121(7):582-91. doi: 10.1111/apm.12043. Epub 2013 Mar 13.

PMID:
23489260
2.

Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples.

Tsui KH, Juang HH, Lee TH, Chang PL, Chen CL, Yung BY.

Acta Pharmacol Sin. 2008 Mar;29(3):364-70. doi: 10.1111/j.1745-7254.2008.00747.x.

3.

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR.

Dig Dis Sci. 2006 Aug;51(8):1371-9. Epub 2006 Jul 26.

PMID:
16868827
4.

Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial.

Zhou F, Li N, Jiang W, Hua Z, Xia L, Wei Q, Wang L.

World J Surg Oncol. 2012 Dec 18;10:274. doi: 10.1186/1477-7819-10-274.

5.

Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.

Xu CC, Yue L, Wei HJ, Zhao WW, Sui AH, Wang XM, Qiu WS.

Pathol Res Pract. 2013 Aug;209(8):479-85. doi: 10.1016/j.prp.2013.04.017. Epub 2013 Jun 7.

PMID:
23822993
6.

HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.

Liu W, Zhong S, Chen J, Yu Y.

J Clin Gastroenterol. 2012 Apr;46(4):e31-7. doi: 10.1097/MCG.0b013e31823457ea.

PMID:
22064554
7.

HER-2/neu overexpression is an independent prognostic factor in colorectal cancer.

Park DI, Kang MS, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Han WK, Kim H, Ryu SH, Sepulveda AR.

Int J Colorectal Dis. 2007 May;22(5):491-7. Epub 2006 Sep 1.

PMID:
16947041
8.

Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.

Tsui KH, Cheng AJ, Chang Pe, Pan TL, Yung BY.

Urology. 2004 Oct;64(4):839-44.

PMID:
15491744
9.

Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray.

Rakhshani N, Kalantari E, Bakhti H, Sohrabi MR, Mehrazma M.

Asian Pac J Cancer Prev. 2014;15(18):7597-602.

10.

Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.

Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL Jr, Soares FA.

J Clin Oncol. 2011 Aug 1;29(22):3030-6. doi: 10.1200/JCO.2010.33.6313. Epub 2011 Jun 27.

11.

Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray.

Ismail HM, Moneer M, El-Baradie M, Khorshid O, Touny A.

J Egypt Natl Canc Inst. 2007 Jun;19(2):147-57.

12.

Prognostic significance of HER2/neu expression in gastric cancer.

Ananiev J, Gulubova M, Manolova I, Tchernev G.

Wien Klin Wochenschr. 2011 Jul;123(13-14):450-4. doi: 10.1007/s00508-011-0025-9. Epub 2011 Jul 11.

PMID:
21739203
13.
14.

Clinicopathologic Implications of Eukaryotic Initiation Factor 3f and Her-2/neu Expression in Gastric Cancer.

Cheng Y, Zhou J, Li H.

Clin Transl Sci. 2015 Aug;8(4):320-5. doi: 10.1111/cts.12263. Epub 2015 Feb 14.

PMID:
25684180
15.

Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer.

Spizzo G, Obrist P, Ensinger C, Theurl I, Dünser M, Ramoni A, Gunsilius E, Eibl G, Mikuz G, Gastl G.

Int J Cancer. 2002 Apr 20;98(6):883-8.

16.

HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.

Tan D, Deeb G, Wang J, Slocum HK, Winston J, Wiseman S, Beck A, Sait S, Anderson T, Nwogu C, Ramnath N, Loewen G.

Diagn Mol Pathol. 2003 Dec;12(4):201-11.

PMID:
14639106
17.

[Association of HER-2/neu expression with prognosis of gastric cancer].

Chen B, Luo RC, Cui F, Qian XY.

Nan Fang Yi Ke Da Xue Xue Bao. 2006 Mar;26(3):344-7. Chinese.

18.

Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.

Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S.

Cancer. 2005 Oct 1;104(7):1391-7.

19.

Relation between transforming growth factor-β1 expression, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers.

Ananiev J, Gulubova M, Tchernev G, Penkova M, Miteva R, Julianov A, Manolova I.

Wien Klin Wochenschr. 2011 Nov;123(21-22):668-73. doi: 10.1007/s00508-011-0078-9. Epub 2011 Oct 24.

PMID:
22015652
20.

c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation.

Quaranta M, Daniele A, Coviello M, Savonarola A, Abbate I, Venneri MT, Paradiso A, Stea B, Zito A, Labriola A, Schittulli F.

Tumori. 2006 Jul-Aug;92(4):311-7.

PMID:
17036522
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk